Literature DB >> 6115730

Assessment of beta blockade with propranolol.

W D Hager, H J Pieniaszek, D Perrier, M Mayersohn, V Goldberger.   

Abstract

Each of seven subjects received on a weekly basis placebo or 10, 20, 40, 80, or 160 mg propranolol orally four times daily. The effect of propranolol on the resting heart rate and the heart rate responses to the Valsalva maneuver, tilt, isoproterenol, and maximal exercise were measured. Coefficients of determination were calculated from the individual dose-response curves. The results indicate that the resting heart rate and the tachycardiac response to the Valsalva maneuver and tilt cannot be used to estimate beta blockade. Propranolol concentrations correlated well (mean r2 = 0.80) with the isoproterenol dose ration minus one, but isoproterenon challenges appear clinically inapplicable. Reduction in maximal exercise tachycardia correlated best with propranolol concentrations (mean r2 = 0.89) but, to the extent that exercise could not be performed, there was no reliable way of clinically documenting beta blockade and only the serum concentration of propranolol was available as an indicator of appropriate therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6115730     DOI: 10.1038/clpt.1981.161

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Bronchoconstriction of the asthmatic airway by inhaled and ingested propranolol.

Authors:  K M Latimer; R E Ruffin
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Pharmacokinetics and pharmacodynamics of conventional and controlled-release formulations of metipranolol in man.

Authors:  R Lapka; T Sechser; V Rejholec; M Peterková; M Votavová
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  The effect of propranolol on exercise induced tachycardia is determined by plasma concentration and the density of adrenergic receptors on leukocytes.

Authors:  K Tawara; E Steiner; C von Bahr
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

4.  Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man.

Authors:  A Wellstein; D Palm; H F Pitschner; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade.

Authors:  K T Murray; C Reilly; R P Koshakji; D M Roden; M D Lineberry; A J Wood; L A Siddoway; J T Barbey; R L Woosley
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

6.  Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension.

Authors:  P Calès; D Grasset; A Ravaud; C Meskens; M Blanc; J P Vinel; J Cotonat; J P Pascal
Journal:  Br J Clin Pharmacol       Date:  1989-06       Impact factor: 4.335

7.  Propranolol treatment in children with tetralogy of Fallot alters the response to isoprenaline after surgical repair.

Authors:  C Barazzone; C Jaccard; M Berner; P Dayer; J C Rouge; I Oberhansli; B Friedli
Journal:  Br Heart J       Date:  1988-08

8.  Heart rate control in hypertensive patients treated by captopril.

Authors:  A Sturani; C Chiarini; E Degliesposti; A Santoro; A Zuccalà; P Zucchelli
Journal:  Br J Clin Pharmacol       Date:  1982-12       Impact factor: 4.335

9.  Ethanol-induced inhibition of hepatic uptake of propranolol in perfused rat liver and in man.

Authors:  P Dorian; E M Sellers; H L Kaplan; G Carruthers; C Hamilton; V Khouw
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.